Laura Carter, Ph.D.

Chief Scientific Officer

Laura Carter, Ph.D. has served as our Chief Scientific Officer since April 2021, previously having served as our Senior Vice President, Research & Translational Biology since joining Gossamer in March 2019. Dr. Carter has over 20 years of industry experience spanning target identification and validation activities through Phase 2 clinical trials in multiple therapeutic areas. Prior to joining Gossamer, she was Senior Vice President, Biology at Lycera Corporation, where she led the development of several immunology and immuno-oncology clinical product candidates. Before joining Lycera, she was a scientific director in the respiratory, inflammation and autoimmunity group at MedImmune, where she was responsible for overseeing research and development of treatments for autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis. Prior to MedImmune, she was a senior research investigator in the inflammation biology and translational science department at Array Biopharma. She started her career in industry at Wyeth, where, among other accomplishments, her basic science studies were critical in identifying and characterizing the negative regulatory role of PD-1:PD-L interactions on T cell function in vitro and in vivo.